Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

This publication has 29 references indexed in Scilit:

• Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
  Proceedings of the National Academy of Sciences, 2008
• Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
  Journal of Clinical Oncology, 2008
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
  Clinical Cancer Research, 2008
• Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers ofin vivoresponse
  Leukemia & Lymphoma, 2008
• The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines
  Cancer Research, 2007
• Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium
  Journal of Clinical Oncology, 2007
• Proteasome inhibitors: antitumor effects and beyond
  Leukemia, 2006
• A loss-of-function RNA interference screen for molecular targets in cancer
  Nature, 2006
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
  The Journal of Experimental Medicine, 2003
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
  Nature, 2000